Light Obscuration May Not be Enough to Detect SVPs in your Drug Product

Did you know that subvisible particles (SVPs) are the leading cause of drug product recalls? Despite being tiny, these particles have a big impact on biologic, cell, and gene therapies – not only limiting a product’s shelf life, but also comprising patient safety. For this reason, injectable drugs face strict requirements to be virtually free […]

Identifying Stable Biologic Candidates During CLD: Leveraging the Power of Immunoassays

CHO cell line development (CLD) has revolutionized modern therapeutic antibody production due to their scalability benefits, ability to produce proteins with the necessary mammalian posttranslational modifications, and large yield protein titers.1 To meet the exponentially growing demand, CHO cell line developers have focused their attention on maximizing titer. However, newer and more complex biologic modalities […]